Medivir - We develop pharmaceuticals

Home
Corporate
Operations
- R & D
- Project Portfolio
- Our projects
  - Xerclear
  - TMC435
  - HCV POL
  - MIV-710 Cathepsin K
  - MIV-711 Cathepsin K
  - HIV PI
  - BACE
  - Cathepsin S
  - COPD
  - Renin
  - Valomaciclovir
  - Alovudine
  - Lagociclovir
  - MIV-150
  - MIV-160
  - MIV-410
- Technologies
- Patents
IR & Media
Career and Contact
Search

Latest reports
INTERIM REPORT, 1 JANUARY – 30 SEPTEMBER 2009
HALF-YEAR INTERIM REPORT, 1 JANUARY – 30 JUNE 2009

Forthcoming reports 2010
The Twelve-month Financial Statement will be published on 18 February
The Three-month Interim Report will be published on 29 April
The Annual General Meeting will be held on 29 April

Lipsovir® approved in both the US and Europe

Our cold sore product has been approved with a commercially very competitive label in both the US and Europe. No product currently marketed for the treatment of cold sores has a corresponding label.

The trademark for the product in Europe will be Xerclear™

Xerclear™ will be available in Sweden as an OTC pharmaceutical from pharmacies in the first half-year 2010.

Eva Arlander, Marketing Director